Disease-Specific and Common HLA and Non-HLA Genetic Markers in Susceptibility to Rheumatoid Arthritis, Type 1 Diabetes Mellitus and Multiple Sclerosis

Tatjana Sjakste1, Jolanta Kalnina1, Natalia Paramonova1, Liene Nikitina-Zake1 and Nikolajs Sjakste2,3,4

1Genomics and Bioinformatics, Institute of Biology of the University of Latvia, Salaspils, Latvia
2Latvian Biomedical Research and Study Centre, Riga LV1067, Latvia
3Department of Medical Biochemistry, Faculty of Medicine, University of Latvia, Riga LV-1004, Latvia
4Latvian Institute of Organic Synthesis, Riga LV-1006, Latvia

Corresponding author: Nikolajs Sjakste, Latvian Institute of Organic Synthesis, No. 21 Aizkraukles Street, Riga LV-1006, Latvia, Tel: 371-29198804; Fax: 371-67034369; E-mail: Nikolajs.Sjakste@lu.lv

Received date: February 28, 2014; Accepted date: March 11, 2016; Published date: March 15, 2016

Abstract

Autoimmune diseases cause numerous health and social problems throughout the world. The common spectrum of autoimmune diseases affect the majority of tissues within the body, including pancreatic beta cells in type 1 diabetes, myelin surrounding nerve axons in Multiple sclerosis, and syndoval joint antigens in Rheumatoid Arthritis (RA). The diseases are likely caused by a complex interaction between multiple HLA- and non-HLA related genes and environmental factors. The well documented co-clustering of autoimmune diseases within families and individuals, together with apparent sharing of number risk genes between the diseases suggests at least some common mechanisms of autoimmune development.

Keywords: Autoimmune diseases; Rheumatoid arthritis; Diabetes mellitus; Multiple sclerosis

Introduction

Autoimmune diseases cause numerous health and social problems throughout the world. The common spectrum of autoimmune diseases affect the majority of tissues within the body, including pancreatic beta cells in type 1 diabetes (T1DM), myelin surrounding nerve axons in Multiple sclerosis (MS) and syndoval joint antigens in Rheumatoid Arthritis (RA). The diseases are likely caused by a complex interaction between multiple HLA and non-HLA related genes and environmental factors. The well documented co-clustering of autoimmune diseases within families and individuals, together with apparent sharing of number risk genes between the diseases suggests at least some common mechanisms of autoimmune development. The three diseases with possibly different manifestations were chosen for this review, the whole field being very vast. The fact all the three diseases with local rather than general symptoms (joints, pancreatic beta cells, myelin) possess common susceptibility factors stresses the importance of these findings.

Rheumatoid arthritis is one of the most common autoimmune diseases; it is chronic, systemic disease, manifesting as progressive, symmetrical deformation of joints, pain and inflammation. Around 1000 new cases of rheumatoid arthritis are diagnosed in Latvia each year. Both genetic and environmental factors play role in the susceptibility to this disease. Many genetic factors are known to increase risk for developing RA. The main genetic factor, involved in susceptibility and pathogenesis of RA is HLA-DRB1 gene in the Major Histocompatibility complex (MHC) on chromosome 6. The main players in the pathogenesis of RA are cytokines; therefore polymorphisms in the regions that might affect expression of the cytokine genes are extensively studied in this disease. Also anti-cytokine agents are successfully used as drugs for this disease. Genome-wide association studies have shown around 200 loci, which might be interesting for rheumatoid arthritis. These loci include genes, mainly involved in immune response and antigen presentation, importance of which for RA is already known and extensively studied including the PTPN22 (protein tyrosine phosphatase expressed by the majority of cells belonging to the innate and adaptive immune systems), STAT4 (signal transducer and activators of transcription, nuclear import of STAT4 is linked to its tyrosine phosphorylation), CTLA4 (cytotoxic T lymphocyte antigen-4, a major negative regulatory molecule for T-cell activation), TRAF1/C5 (tumor necrosis factor-receptor associated factor 1/complement component 5), PAD4 (peptidyl-arginine-deiminase type IV), MIF (cytokine which counteracts the immunosuppressive properties of glucocorticoids) and many others [1-5], as well as others genes with yet unknown function. RA patients can be classified in different clinically significant groups according their genomic traits (ACPA (anti-citrullinated-protein-antibody) positive versus negative [6]. RA is very heterogeneous disease not only concerning the symptoms, genetic predisposition and antibody status, but also concerning variations in response to different therapeutic approaches. Several genes were found to affect the incidence of side effects and patients response to different drugs such as Methotrexate, these are RFC1 (reduced folate carrier) [7], ABCB1 (the gene which encodes an efflux pump, is an ATP-binding cassette of sub-family B, member 1) [8], and MTHFR (methylene tetrahydrofolate dehydrogenase 1) [9,10] genes. Some genes modify effect of anti TNF therapy: TNFA (tumour necrosis factor alpha) [11], interferon (IFN type 1) gene, promoter polymorphisms of interleukin IL-10 and other genes [12]. Efficiency of Azatioprine therapy depends on TPMT gene, sulfasalazine - on NAT2 gene [13]. The RA susceptibility in Latvian population has been studied already [14], data
on TNFA (rs1800629, rs361525), IL6 (rs1800795), IL18 (rs1946518, rs1946519), IL10 (rs1800894, rs1800871, rs1800895, rs1800872), IRE5 (rs3757385, rs2004640, rs19054213), KLF12 (Kruppel-like factor 12; rs1324913) and PTPN22 (rs2476601) associations with the disease are published.

Diabetes mellitus (DM) and its complications cause numerous health and social problems throughout the world. Number of DM patients constantly increases. Diabetes, characterized by persistent elevation of blood glucose levels (hyperglycaemia), occurs due to inadequate production of insulin (type 1 diabetes; T1DM), or resistance to endogenous insulin usually associated with the metabolic syndrome and obesity (type 2 diabetes; T2D). Despite intensive glycemic control, individuals with T1DM and T2DM are predisposed to developing vascular complications [15]. DM and its complications are common in Latvia: in 2010 72654 DM patients were registered, 3891 with T1DM and 68217 with T2DM. Kidney malfunction like microalbuminuria was detected in 2737 patients, proteinuria – in 1092, renal failure – in 228, substitution therapy was indicated to 57 patients, kidney grafts were transplanted to 31 patient. Etiologically T1DM is an autoimmune disease both environmental and hereditary factors being important for susceptibility to it. Several studies have demonstrated a fundamental role for the HLA in the susceptibility of, or protection to T1DM. While HLA remains the strongest genetic risk factor, a number of novel gene variants associated with T1DM have been found through genome-wide studies, some of which have been linked to suspected environmental risk factors. However, jointly non-HLA risk alleles described up till now confer only a small additional risk compared to the effect of HLADR, HLADQ. Variants or polymorphisms in UBASH3A (a suppressor of T cell receptor signalling pathway) and PTPN22 (the protein tyrosine phosphatase nonreceptor type 22) were shown as candidates for development of islet autoimmunity and T1DM when controlling for family history and in presence of the HLA-DR3/4-DQB1*0302 genotype. Polymorphisms in the insulin INS gene predicted development of T1DM. Although the effect of each individual gene is small, the combination of T1DM family history, the HLA-DR3/4-DQB1*0302 genotype, and the susceptibility variants of PTPN22, UBASH2, and INS were reported to increase 16-fold the risk of islet autoimmunity and 40-fold of T1DM. The IFIH1 (interferon induced with helicase C domain 1, also known as MDA5, or melanoma differentiation-associated gene 5) linkage disequilibrium block on chromosome 2q has also been found to be associated with T1DM in GWAS and increased gene expression is associated with risk of T1DM [16].

Diabetic kidney disease, or diabetic nephropathy (DN), is a major complication of diabetes and the leading cause of end-stage renal disease (ESRD) that requires dialysis treatment or kidney transplantation. In addition to the decrease in the quality of life, DN accounts for a large proportion of the excess mortality associated with T1DM. Meta-analysis of GWAS results revealed an association of ESRD with the rs7583877 in the DNA-binding protein AFF3 gene and a chromosome 15q26 intergenic SNP locating between two growth and development-related RGMA (repulsive guidance molecule a) and MCTP2 (multiple C2-domains with two transmembrane regions 2) genes. Functional data suggest that AFF3 influences renal tubule fibrosis via the transforming growth factor-beta (TGF-β1) pathway. The strongest association with DN as a primary phenotype was seen for an intronic SNP in the receptor tyrosine kinase ERBB4 gene [17].

It should be mentioned that some genetic predisposition factors apparently are not spotted in GWAS studies, although sufficient association is revealed in studies with individual genes. DNA damage by endogenous free radicals and further ineffective repair of these lesions is considered to be one of the etiological factors of DM [18,19]. Oxidative stress and abnormal production of nitric oxide are of the main causes of increased DNA breakage in DM leading to development of its complications. Thus polymorphism of genes responsible for the free radical production and scavenging appear to be of special interest. Endothelial nitric oxide synthase (eNOS) polymorphisms have been reported to be strongly associated with DN risk, there are also reports on association of some alleles of inducible NO synthase (iNOS) gene with DM complications [20]. Increased DNA breakage due to oxidative stress determines importance of DNA repair genes (base excision repair gene MUTYH, X-ray repair cross complementing group 1 XRCC1 and 8-Oxoguanine-DNA glycosylase hOGG1) in resistance or susceptibility to DM [21,22].

Multiple sclerosis (MS) is most common, clinically extremely heterogeneous, chronic inflammatory disease of the CNS affecting about 2.5 million people around the world (2500 of them in the Latvia), presumably young adults, with onset usually at the second to fourth decade of life and, similarly to other autoimmune diseases, women being affected 3-4 times more frequent than men [23]. Pathologically, there are perivascular infiltrates of Cd4+ and Cd8+ T cells in the CNS white matter and meninges with demyelinating lesions and loss of axons in both white and grey matter [24]. List of different MS subtypes includes the relapsing-remitting (RR), secondary progressive (SP0 and primary progressive (PP), and within each subtype there is also considerable individual variation in disease course [25].

The cause of MS is not clear. Disease develops in genetically susceptible individuals with the contributions of environmental factors, such as infection, sunlight exposure, and vitamin D deficiency [26]. There are also marked changes in systemic immune function with loss of regulatory T cell (Treg) function and increases in myelin-reactive Cd4+ T cells [27-29].

Unbiased genome-wide association scans have identified susceptibility loci in regions containing genes with immune, co-stimulatory, signal transduction functions and vitamin D related, including, for example, the CD6, CD25, CD40, CD58, HLA-A, HLA-B, HLA-DRB1, IL2RA, IL7R, IL12A, IRF8, the Janus kinase (JAK)/signal transducer and activator of transcription STAT3, gene of the receptor for tumour necrosis factor-α TNFRSF1A, CYP27B1 (1a-hydroxylase - an enzyme, which converts vitamin D to its active form) and other genes [30-34]. Osteopontin OPN gene may be involved in MS development and especially, progression and cytokines may be suggested as therapeutic target to counteract MS progression [35].

According to the ICSNPathway analysis (Identify candidate Causal SNPs and Pathway analysis) applied to the MS GWAS dataset [36], 9 HLA and 7 non-HLA candidate SNPs and 5 and 10 candidate causal pathways respectively are mostly susceptible to MS including risk HLA loci: rs1802127 (MHC5), rs9277471 (HLA-DPB1), rs8084 and rs7192 (HLA-DRA), rs2072895 and rs2735059 (HLA-F), rs915669, rs915668 and rs1063320 (HLA-G); and risk non-HLA loci: rs5896 (F2, prothrombin), rs8181979 (SHC1; Src homology 2 domain containing transforming protein 1), rs2957605 (TAF2, RNA polymerase II), rs669 (A2 M; M-type phospholipase A2 receptor), rs2228043 (IL6ST; interleukin 6 signal transducer ), rs1061662 (TNFRSF1B), rs1801516 (ATM). The most strongly associated pathways were the rs1802127 to MHC5 to meiotic recombination and meiotic cell cycle and rs5896 to
Evidence underlines the importance of microRNAs (miRNAs) such as miR326, miR-323, miR-223, miR-23a, miR-15b and others in the MS pathogenesis [38,39]. It was shown [39] that rs1044165 (miR-223) likely acts as MS protective factor, while rs3745453 (miR-23a) seems to be a risk factor for MS. Extracellular miRNAs appear to be taken in consideration as a new source for both biomarker and risk factor identification and therapeutic drug discovery.

The RA, T1DM and MS common elements of genetic architecture

Well documented co-clustering of autoimmune diseases within families and individuals are in good agreement with apparent sharing of a number of risk genes and polymorphic loci between particular diseases. A whole genome linkage scan by microsatellite markers provided significant evidence of linkage between the T1DM and MS [40]. At least the IL7R-CAPSL (interleukin 7 and calcyphosine-like protein) CD226, II2RA, HLA Class I, HLA Class II, CLEC16A, RGS1 (regulator of G protein signaling), ZMIZ1 (zinc finger, MIZ-type containing 1), TNFSF14 (tumor necrosis factor (ligand) superfamily, member 14), SOXB (SRY (sex determining region Y)-box 3), CLEC11 and NFKB1 genes are susceptible to both the T1DM and MS. RA and MS share the susceptibility to variations in VCAM1 (vascular cell adhesion molecule 1), IL22RA2, PVT1, CLEC11 and CD37 [32,41,42]. Despite large number of genes reported to be associated with each given disease, some polymorphic loci appear to be common for several diseases. These are, for example, the rs2104286 of the IL2RA sharing by MS and T1DM [43] and the rs10466829 of the CLEC11 sharing by RA, T1DM and MS [32]. The proteosomal PSMA6/PSMC6/PSMA3 gene cluster on Chromosome 14 [44] also appears to be a good candidate for association with several autoimmune diseases. Besides formerly revealed association of several polymorphisms in the cluster with Graves' disease [45] and juvenile idiopathic arthritis [46,47] our recent findings indicate associations with T1DM [48] and MS [49]. Childhood asthma [50] and childhood obesity [51,52], pathologies with a pronounced autoimmune and immunological component are also associated with some genetic variations in this cluster.

Functions of some non-HLA genes associated with autoimmune diseases are listed in Table 1. Several genes are involved in signaling pathways in T-lymphocytes (PTPN22, STAT 4, CTLA-4, PADI4, MIF, PADI4), apoptosis (TRAF1/C5, TNFSF14), calcium and G-protein-dependent signalling pathways (CLEC16A, CAPSL, RGS1) and other pathways.

| No. | Abbreviated gene name | Full gene name | Function of the protein | Associated diseases |
|-----|-----------------------|----------------|-------------------------|---------------------|
| 1.  | PTPN22                | Protein tyrosine phosphate | An inhibitor of T-cell activation, contributes to signalling cascades (TLR, TCR, BCR pathways) initiated in immune cells, including B cells and cells of the innate immune system. | RA, systemic lupus erythematosus (SLE), T1DM, Hashimoto disease (HD), Graves’ disease (GD), vitiligo [53] |
| 2.  | STAT 4                | Signal transducer and activators of transcription 4 | Part of the JAK-STAT signalling pathway, expressed only spermatoza, myeloid cells, and T lymphocytes. STAT 4 is activated by tyrosine phosphorylation in response to interleukin-12 (IL-12) treatment of T cells, involved in T helper cell function. | RA, SLE, Sjögren’s syndrome, juvenile idiopathic arthritis (JIA), GD, myasthenia gravis [54,55] |
| 3.  | CTLA-4                | Cytotoxic T-lymphocyte antigen-4 | Cell surface molecule involved in the regulation of signaling pathways affecting T-cell responses. Activation results in decreased T-lymphocyte activity and regulates the immune response. | RA, SLE, T1DM, Addison’s disease (AD), Vitiligo, MS, HD [56,57] |
| 4.  | TRAF1/C5              | Tumor necrosis factor-receptor associated factor 1/complement component 5 locus | The TNF receptor associated factor 1 (TRAF1) is an adaptor protein, it TNF family members, to downstream signaling networks. TRAF1 is implicated in cell growth, proliferation, apoptosis, bone turnover, cytokine activation. | RA [58] |
| 5.  | PADI4                 | Peptidyl-arginine-deiminase type IV | The PADI4 enzyme is expressed in T and B cells, neutrophils, eosinophils, monocytes. It mediates the citrullination of histones/conversion of arginine residues to citrulline. Target for autoantibodies in RA. | RA [58,59] |
| 6.  | MIF                   | Macrophage migration inhibitory factor | A T cell derived cytokine, inhibits the random migration of macrophages in vitro and promotes macrophage accumulation during delayed-type hypersensitivity reactions. | T1DM, RA [60] |
| 7.  | UBAH3A                | Ubiquitin associated and SH3 domain containing A | Belongs to T-cell ubiquitin ligand (TULA) family, facilitates growth factor withdrawal-induced apoptosis in T cells. An active phosphatase capable of dephosphorylating | T1DM [61,62] |
8. **STAT3**

*Signal transducer and activator of transcription 3 (acute-phase response factor)*

STAT 3 protein is activated through phosphorylation by the receptor associated kinases in response to various cytokines and growth factors including IFNs, EGF, IL5, IL6, HGF, LIF and BMP2. Then it forms homo- or heterodimers that translocate to the cell nucleus where it acts as transcription activator of a variety of genes in response to cell stimuli, and thus plays a key role in many cellular processes such as cell growth and apoptosis.

MS [30]

9. **CLEC16A**

*C-type lectin domain family 16, member A*

A transmembrane calcium-dependent (C-type) lectin-like receptor

MS, RA, T1DM [42]

10. **CAPSL**

*Calcycrophosine-like protein*

Calcium sensor and calcium signal modulator.

T1DM [32]

11. **RGS1**

*Regulator of G protein signaling*

Regulator of G protein signaling

T1DM, MS [32]

12. **ZMIZ1**

*zinc finger, MiZ- type containing 1*

A member of the PIAS (protein inhibitor of activated STAT) family of proteins. The encoded protein regulates the activity of various transcription factors, including the androgen receptor, Smad3/4, and p53. The encoded protein may also play a role in sumoylation.

T1DM, MS [32]

13. **TNFSF14**

*tumor necrosis factor ligand family, member 14*

A member of the tumor necrosis factor (TNF) ligand family. Functions as a costimulatory factor for the activation of lymphoid cells, stimulates the proliferation of T cells, and trigger apoptosis of various tumor cells.

T1DM, MS [32]

14. **VCAM1**

*vascular cell adhesion molecule 1*

A cell surface sialoglycoprotein expressed by cytokine-activated endothelium, mediates leukocyte-endothelial cell adhesion and signal transduction.

T1DM, RA [32]

15. **SOXB**

*SRY (sex determining region Y)-box 3*

Member of SOX (SRY-related HMG-box) family of transcription factors involved in the regulation of embryonic development and in the determination of the cell fate.

T1DM, MS [32]

16. **Pvt1 oncogene (non-protein coding)**

Oncogene, associated with several types of cancer and renal diseases.

T1DM, RA [32,41,42]

### Table 1: Non HLA genetic markers of autoimmune diseases.

Coexistence of autoimmune diseases has been recently reviewed and statistically evaluated suggesting association of diseases and their common origin [63]. However the problem is only in the beginning of experimental evaluation and has to be very topical in genomic studies in nearest future.

**Acknowledgement**

The work was supported from the Grant of the Latvian Council of Science 278/2012 and the National Research Programme "Biomedicine 2014."

**References**

1. Julià A, Ballina J, Cañete JD, Balsa A, Tornero-Molina J, et al. (2008) Genome-wide association study of rheumatoid arthritis in the Spanish population: KLF12 as a risk locus for rheumatoid arthritis susceptibility. Arthritis Rheum 58: 2275-2286.

2. Morgan AW, Robinson JI, Conaghan PG, Martin SG, Hensor EM, et al. (2010) Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB, PTPN, OLIG3/TNFAIP, STAT4 and TRAF1/C5 in an inception cohort. Arthritis Res Ther 12: R57.

3. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, et al. (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42: 508-514.

4. Mohammed RH, Pasha HF, El-Shahawy EE (2012) Influence of TRAF1/C5 and STAT4 genes polymorphisms on susceptibility and severity of rheumatoid arthritis in Egyptian population. Cell Immunol 273: 67-72.

5. Yang, HC, Chang LC, Liang YJ, Lin CH, Wang PL (2012) A genome-wide homozygosity association study identifies runs of homozygosity associated with rheumatoid arthritis in the human major histocompatibility complex. PLoS One 7: e34840.

6. Padyukov L, Seielstad M, Ong RT, Ding B, Rönnelid J, et al. (2011) A genome-wide association study suggests contrasting associations in...
22. Chiusolo P, Giammarco S, Bellesi S, Metafuni E, Piccirillo N, et al. (2012) The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. Cancer Chemother Pharmacol 69: 691-696.

23. Takatori R, Takahashi KA, Tokunaga D, Hojo T, Fujisaka M, et al. (2006) ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 24: 546-554.

24. Choe JY, Park SH, Kim SK (2011) MTHFR polymorphisms, C677T and

25. Owen SA, Lunt M, Bowes J, Hider SL, Bruce IN, et al. (2013) MTHFR

26. Compston A, Confavreux C, Lassmann H, McDonald I, Noseworthy J, et al. (2011) Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies polymorphisms with at seven loci. Arthritis Rheum 63: 645-653.

27. Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, et al. (2008) International MS Genetics Consortium. Meta-analysis of genome scans and replication identityCD6, IRF8 and TNFRF1A as new multiple sclerosis susceptibility loci. Nat Genet 41: 776-782.

28. Soejima M, Kawaguchi Y, Hara M, Kamatani N (2008) Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis. J Rheumatol 35: 724.

29. Mihailova A, Mikazane H, Klovins J, Nikitina-Zake L (2011) Association of protein tyrosine phosphatase non-receptor 22 (PTPN22) rs2476601 and Kruppel-like factor 12 (KLF12) rs1324913 single nucleotide polymorphisms with rheumatoid arthritis in a Latvian population. Scand J Rheumatol 40: 491-492.

30. Sharma A, Bernatchez PN, de Haan JB (2012) Targeting endothelial dysfunction in vascular complications associated with diabetes. Int J Vas Med 2012: 750126.

31. Nokoff N, Rewers M (2013) Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals. Ann N Y Acad Sci 1281: 1-15.

32. Sandholn N, Salem RM, McKnight AJ, Brennam EP, Forbslom C, et al. (2012) New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 8: e1002921.

33. Selvaraju V, Josh M, Suresh S, Sanchez JA, Maulik N, et al. (2012) Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease—an overview. Toxicol Mech Methods 22: 330-335.

34. Tatsch E, Bochi GV, Piva SJ, De Carvalho JA, Kobler H, et al. (2012) Association between DNA strand breakage and oxidative, inflammatory and endothelial biomarkers in type 2 diabetes. Mutat Res 732: 16-20.

35. Uthra S, Raman R, Mukesh BN, Rajkumar SA, Kumari P, et al. (2010) Diabetic retinopathy: Validation study of ALK, RAGE, INOS and TNFB gene variants in a south Indian cohort. Ophthalmic Genet 31: 244-251.

36. Kasznicki J, Krupa R, B, asiaK, J, Drewnowski J (2009) Association between polymorphisms of the DNA repair genes XRCC1 and hOGG1 and type 2 diabetes mellitus in the Polish population. Pol Arch Med Wewn 119: 122-128.

37. Chen H, Sun G, Guo W, Meng R, Du H, et al. (2011) AluYb8 insertion in the MUTYH gene is related to increased 8-OHdG in genomic DNA and could be a risk factor for type 2 diabetes in a Chinese population. Mol Cell Endocrinol 332: 301-305.

38. Compston A, Confaivreux C, Lassmann H, McDonald I, Noseworthy J, et al. (2006) McAlpine's multiple sclerosis. Philadelphia: Churchill Livingstone/Elsevier 2006.

39. Kornb B, Storb MK, Weisser R, Wallstroem E, Stetterf E, et al. (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axon injury in active, inactive and remyelinated lesions. Am J Pathol 157: 267-276.

40. Miller AE (2011) Multiple sclerosis: where will we be in 2020? Mt Sinai J Med 78: 269-279.

41. Schneider-Holendorf T, Stupper MP, Weidenfeller C, Zouzyl A, Simon OJ, et al. (2010) Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. Eur J Immunol 40: 3581-3590.

42. Venken K, Hellingis N, Hansen K, Rumann JS, Stinissen P (2010) Memory CD4+CD127high T cells from patients with multiple sclerosis produce IL-17 in response to myelin antigens. J Neuroimmunol 226: 185-191.

43. Dominguez-Villar M, Baecher-Allan CM, Hafer DA (2011) Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med 17: 673-675.

44. De Jager PL, Jia X, Wang PL, de Bakker L, Ottoboni L, et al. (2009) International MS Genetics Consortium. Meta-analysis of genome scans and replication identityCD6, IRF8 and TNFRF1A as new multiple sclerosis susceptibility loci. Nat Genet 41: 824-828.

45. International Multiple Sclerosis Genetics Consorciu (IMSGC) (2010) IL12A, MPHOSPH9/CDK2AP and RGS are novel multiple sclerosis susceptibility loci. Genes Immun 11: 397-405.

46. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) (2009) Genome-wide association study identifies new multiple sclerosis susceptibility locus on chromosomes 12 and 20. Nat Genet 41: 215-220.

47. Koller DM, Severson CA, Moussisian N, De Jager PL, Hafer DA (2011) The CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4+ T cell proliferation. J Immunol 187: 3286-3291.

48. Comi C, Cappellano G, Chiocchetti A, Orielli E, Buttimi S, et al. (2012) The impact of osteopontin gene variations on multiple sclerosis development and progression. Clin Dev Immunol 2006: 212893.

49. Zhang K, Chang S, Cui S, Guo L, Zhang L, et al. (2011) ICSNPathway: identify candidate causal SNPs and pathways from genome-wide association study by one analytical framework. Nucleic Acids Res 39: W437-W443.

50. Song GG, Choi SJ, Ji JD, Lee YH (2013) Genome-wide pathway analysis of a genome-wide association study on multiple sclerosis. Mol Biol Rep 40: 2557-2564.

51. Fenoglio C, Ridolfi E, Gilamberti D, Scarpi E (2012) MicroRNAs as active players in the pathogenesis of multiple sclerosis. Int J Mol Sci 13: 13227-13239.

52. Ridolfi E, Fenoglio C, Cantonii C, Calvi A, De Riz M, et al. (2013) Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis. Int J Mol Sci 14: 4375-4384.

53. Pitazlis M, Zavatelli P, Murrut R, Deidde E, Zolezziwska E, et al. (2008) Genetic loci linked to type 1 diabetes and multiple sclerosis families in Sardinia. BMC Med Genet 9: 3.

54. Brand OJ, Gough SC (2011) Immunogenetic mechanisms leading to thyroid autoimmunity: recent advances in identifying susceptibility genes and regions. Curr Genomics 12: 536-541.

55. Zolezziwska M, Costa G, Pitazlis M, Cocco E, Melis C, et al. (2009) Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes Immun 10: 15-17.

56. Maier LM, Lowe CE, Cooper J, Downes K, Anderson DE, et al. (2009) IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes
susceptibility and soluble interleukin-2 receptor production. PLoS Genet 5: e1000322.

44. Sjakste T, Paramonova N, Shi-Shin Wu L, Zemeckiene Z, Sitkauskiene B, et al. (2014a) PSMA6 (rs2277460, rs1048990), PSMC6 (rs2295826, rs2295827) and PSMA3 (rs2348071) genetic diversity in Latvians, Lithuanians and Taiwanese. Meta Gene 2: 283-298.

45. Sjakste T, Eglite J, Sochnevs A, Marga M, Pirags V, et al. (2004) Microsatellite genotyping of chromosome 14q13.2-14q13 in the vicinity of proteasomal gene PSMA6 and association with Graves’ disease in the Latvian population. Immunogenetics 56: 238-243.

46. Sjakste T, Trapina I, Rumba-Rozenfelde I, Lunin R, Sugoka O, et al. (2010) Identification of a novel candidate locus for juvenile idiopathic arthritis at 14q13.2 in the Latvian population by association analysis with microsatellite markers. DNA Cell Biol 29: 543-551.

47. Sjakste T, Paramonova N, Rumba-Rozenfelde I, Trapina I, Sugoka O, et al. (2014b) Juvenile Idiopathic Arthritis Subtype- and Sex-specific Associations with Genetic Variants in the PSMA6/PSMC6/PSMA3 Gene Cluster. Pediatr Neonatol 55: 393-403.

48. Kalnina J, Paramonova N, Nikitina-Zake L, Sjakste N, Sjakste T (2014) Study of association between polymorphisms in the PSMB5 (rs11543947) and PSMA3 (rs2348071) genes and multiple sclerosis in Latvians. Biopolym Cell 30: 305-309.

49. Paramonova N, Kupca S, Rumba-Rozenfelde I, Sjakste N, Sjakste T (2014b) Association between the PSMB5 and PSMC6 genetic variations and children obesity in the Latvian population. Biopolym Cell 30: 477-480.

50. Fousteri G, Liosis SN, Battaglia M (2013) Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity. Clin Immunol 149: 556-565.

51. Reich NC (2013) STATs get their move on. JAKSTAT 2: e27080.

52. Kristiansen OP, Larsen ZM, Pociot F (2000) CTLA-4 in autoimmune diseases--a general susceptibility gene to autoimmunity? Genes Immun 1: 184.

53. Kurki J, Besenyei T, Laki J, Giann TT, Míkecz K, et al. (2013) Genetics of rheumatoid arthritis - a comprehensive review. Clin Rev Allergy Immunol 45: 170-179.

54. Anzilotti C, Pratesi F, Tommasi C, Migliorini P (2010) Peptidylarginine deiminase 4 and citrullination in health and disease. Autoimmun Rev 9: 158-160.

55. Sánchez-Zamora YI, Rodriguez-Sosa M (2014) The role of MIF in type 1 and type 2 diabetes mellitus. J Diabetes Res 2014: 804519.

56. Cerosaletti K, Buckner JH (2012) Protein tyrosine phosphatases and type 1 diabetes: genetic and functional implications of PTPN2 and PTPN22. Rev Diabet Stud 9: 188-200.

57. Tseng KJ (2009) TULA-family proteins: an odd couple. Cell Mol Life Sci 66: 2949-2952.

58. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, Anaya JM (2012) Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis 2012: 254319.